Suchergebnisse - "Buadi, Francis K"

PubPharm (383)

1

An Open-Label Phase I Study of Metformin and Nelfinavir in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma

enthalten in: Clinical lymphoma, myeloma & leukemia | 2024

von Alodhaibi, I. | Ailawadhi, S. | Burbano, G. | +5

2

Treatment patterns for AL amyloidosis after frontline daratumumab, bortezomib, cyclophosphamide, and dexamethasone treatment failures

enthalten in: Leukemia | 2024

von Zanwar, S. | Gertz, M. | Muchtar, E. | +19

3

Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomide

enthalten in: Blood cancer journal | 2024

von Goel, U. | Charalampous, C. | Kapoor, P. | +18

4

Predictors and Impact of Timing of Disease Progression Following Primary Therapy in Multiple Myeloma

enthalten in: Clinical lymphoma, myeloma & leukemia | 2024

von Goldman-Mazur, S. | Visram, A. | Rajkumar, S. | +14

5

Mode of progression in smoldering multiple myeloma : a study of 406 patients

enthalten in: Blood cancer journal | 2024

von Abdallah, N. | Lakshman, A. | Kumar, S. | +14

UpdateOf: Res Sq. 2023 Oct 23;:. - PMID 37961238

6

Daratumumab-lenalidomide and daratumumab-pomalidomide in relapsed lenalidomide-exposed or refractory multiple myeloma

enthalten in: Anti-cancer drugs | 2024

von Alhaj Moustafa, M. | Parrondo, R. | Abdulazeez, M. | +15

7

Muscle and fat composition in patients with newly diagnosed multiple myeloma

enthalten in: Blood cancer journal | 2023

von Abdallah, N. | Nagayama, H. | Takahashi, N. | +19

8

Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory multiple myeloma

enthalten in: Blood cancer journal | 2023

von Charalampous, C. | Goel, U. | Kapoor, P. | +19

9

Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas

enthalten in: Blood | 2023

von Yadav, U. | Kumar, S. | Baughn, L. | +30

CommentIn: Blood. 2023 Nov 30;142(22):1849-1850. - PMID 38032673

10

Natural history, predictors of development of extramedullary disease, and treatment outcomes for patients with extramedullary multiple myeloma

enthalten in: American journal of hematology | 2023

von Zanwar, S. | Ho, M. | Lin, Y. | +20

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[39]